Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: Results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial

Annals of Oncology

Volumn 23, Issue 1, 2012, Pages 200-205

  Durand, J P ^a   Deplanque, G ^b   Montheil, V ^a   Gornet, J M ^c   Scotte, F ^d   Mir, O ^a   Cessot, A ^a   Coriat, R ^a   Raymond, E ^e   Mitry, E ^f   Herait, P ^a   Yataghene, Y ^g   Goldwasser, F ^a  

^a Université Paris Descartes ^*  (France)

^b SAINT JOSEPH HOSPITAL   (France)

^c SAINT LOUIS HOSPITAL   (France)

^d HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^e BEAUJON HOSPITAL   (France)

^f ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^g SANOFI   (France)

Author keywords

Neurotoxicity; Oxaliplatin; Venlafaxine

Indexed keywords

OXALIPLATIN; PLACEBO; VENLAFAXINE;

ADULT; AGED; ANOREXIA; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; COLORECTAL CANCER; CONSTIPATION; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG INDUCED HEADACHE; DYSGEUSIA; FEMALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROLOGIC EXAMINATION; NEUROPATHIC PAIN; NEUROPATHIC PAIN SYMPTOM INVENTORY; NEUROTOXICITY; ORTHOSTATIC HYPOTENSION; PAIN ASSESSMENT; PERIPHERAL NEUROPATHY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SOMNOLENCE; VOMITING;

EID: 84855177620     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr045     Document Type: Article

References (30)

1. de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000; 18(16): 2938-2947.
2. Tournigand C, Cervantes A, Figer A et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer-a GERCOR study. J Clin Oncol 2006; 24(3): 394-400.
3. André T, Boni C, Mounedji-Boudiaf L et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350(23): 2343-2351.
4. Misset JL, Vennin P, Chollet PH et al. Multicenter phase II-III study of oxaliplatin plus cyclophosphamide vs. cisplatin plus cyclophosphamide in chemonaive advanced ovarian cancer patients. Ann Oncol 2001; 12(10): 1411-1415.
5. Cunningham D, Starling N, Rao S et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358(1): 36-46.
6. Le Chevalier T, Thezenas S, Breton J et al. Randomized phase II study of gemcitabine-oxaliplatin or gemcitabine-cisplatin in chemonaive patients with advanced non-small cell lung cancer (NSCLC)-CLEO 05. J Clin Oncol 2006; 24(18S): Abstract 7097.
7. Mir O, Alexandre J, Ropert S et al. Vinorelbine and oxaliplatin in stage IV nonsmall cell lung cancer patients unfit for cisplatin: a single-center experience. Anticancer Drugs 2009; 20(2): 105-108.
8. Carles J, Esteban E, Climent M et al. Gemcitabine and oxaliplatin combination: a multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer. Ann Oncol 2007; 18(8): 1359-1362.
9. Mir O, Alexandre J, Ropert S et al. Combination of gemcitabine and oxaliplatin in urothelial cancer patients with severe renal or cardiac comorbidities. Anticancer Drugs 2005; 16(9): 1017-1021.
10. Gornet JM, Savier E, Lokiec F et al. Exacerbation of oxaliplatin neurosensory toxicity following surgery. Ann Oncol 2002; 13(8): 1315-1318.
11. Grolleau F, Gamelin L, Boisdron-Celle M et al. A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels. J Neurophysiol 2001; 85(5): 2293-2297.
12. Grothe DR, Scheckner B, Albano D. Treatment of pain syndromes with venlafaxine. Pharmacotherapy 2004; 24(5): 621-629.
13. Davis JL, Smith RL. Painful peripheral diabetic neuropathy treated with venlafaxine HCl extended release capsules. Diabetes Care 1999; 22(11): 1909-1910.
14. Khalifa M, Daleau P, Turgeon J. Mechanism of sodium channel block by venlafaxine in guinea pig ventricular myocytes. J Pharmacol Exp Ther 1999; [291:] 280-284.
15. Durand JP, Brezault C, Goldwasser F. Protection against oxaliplatin acute neurosensory toxicity by venlafaxine. Anticancer Drugs 2003; 14(6): 423-425.
16. Durand JP, Alexandre J, Guillevin L, Goldwasser F. Clinical activity of venlafaxine and topiramate against oxaliplatin-induced disabling permanent neuropathy. Anticancer Drugs 2005; 16(5): 587-591.
17. Bouhassira D, Attal N, Fermanian J et al. Development and validation of the Neuropathic Pain Symptom Inventory. Pain 2004; 108(3): 248-257.
18. Lé vi FA, Zidani R, Vannetzel JM et al. Chronomodulated versus fixedinfusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: a randomized multi-institutional trial. J Natl Cancer Inst 1994; 86(21): 1608-1617.
19. Entsuah R, Chitra R. A benefit-risk analysis of once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Psychopharmacol Bull 1997; 33(4): 671-676.
20. Olver JS, Burrows GD, Norman TR. The treatment of depression with different formulations of venlafaxine: a comparative analysis. Hum Psychopharmacol [2004;] 19(1): 9-16.
21. Gamelin L, Boisdron-Celle M, Delva R et al. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 2004; 10(12 Pt 1): 4055-4061.
22. Hochster HS, Grothey A, Childs BH. Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity. J Clin Oncol 2007; 25(25): 4028-4029.
23. Grothey A, Nikcevich DA, Sloan JA et al. Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7. J Clin Oncol 2011; 29(4): 421-427.
24. Zafir A, Ara A, Banu N. Invivo antioxidant status: a putative target of antidepressant action. Prog Neuropsychopharmacol Biol Psychiatry 2009; 33(2): 220-228.
25. Eren I, Naziroǧlu M, Demirdasx A et al. Venlafaxine modulates depressioninduced oxidative stress in brain and medulla of rat. Neurochem Res 2007; 32(3): 497-505.
26. Lecomte T, Landri B, Beaune P et al. Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clin Cancer Res 2006; 12(10): 3050-3056.
27. Adler V, Yin Z, Fuchs SY et al. Regulation of JNK signalling by GSTp. EMBO J [1999;] 18: 1321-1334.
28. Henderson CJ, McLaren AW, Moffat GJ et al. Pi-Class glutathione S-transferase: regulation and function. Chem Biol Interact 1998; 111-112: 69-82.
29. Elsby R, Kitteringham NR, Goldring CE et al. Increased constitutive c-Jun N-terminal kinase signalling in mice lacking glutathione S-transferase Pi. J Biol Chem 2003; 278: 22243-22249.
30. Cascinu S, Catalano V, Cordella L et al. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2002; 20: 3478-3483.